Tucker Asset Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Tucker Asset Management’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-4	Closed	-$71	–	1547
2023 Q3	$71	Hold	4	–	–	﹤0.01%	1339
2023 Q2	$72	Hold	4	–	–	﹤0.01%	1119
2023 Q1	$50	Hold	4	–	–	﹤0.01%	1144
2022 Q4	$58	Hold	4	–	–	﹤0.01%	799
2022 Q3	$74	Hold	4	–	–	﹤0.01%	834
2022 Q2	$58	Hold	4	–	–	﹤0.01%	632
2022 Q1	$67	Hold	4	–	–	﹤0.01%	552
2021 Q4	$96	Hold	4	–	–	﹤0.01%	442
2021 Q3	$111	Hold	4	–	–	﹤0.01%	374
2021 Q2	$116	Hold	4	–	–	﹤0.01%	343
2021 Q1	$129	Buy	+4	New	+$148	﹤0.01%	335

Other funds holding TARS

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Tucker Asset Management's TARS Position: Q4 2023 in Review

Tucker Asset Management sold out of Tarsus Pharmaceuticals (TARS) in Q4 2023, closing a stake of 4 shares — an estimated $71 sold.

Tucker Asset Management first reported a position in TARS in Q1 2021 and held it in 11 quarters. The position peaked at $129 in Q1 2021. 116 funds tracked by Wall St. Rank hold TARS as of Q4 2023.

Tucker Asset Management reported no remaining Tarsus Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Tucker Asset Management sold 4 Tarsus Pharmaceuticals shares in Q4 2023, an estimated $71.
Tucker Asset Management first reported a position in Tarsus Pharmaceuticals in Q1 2021 and held it in 11 quarters.
Tucker Asset Management's Tarsus Pharmaceuticals position peaked at $129 in Q1 2021.
116 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q4 2023.

Based on Tucker Asset Management's 13F filing for Q4 2023, filed 4 Mar 2024.